Botulinum toxin and occupational therapy for Writer's cramp

Park, Jung E.; Shamim, Ejaz A.; Panyakaew, Pattamon; Mathew, Pawan; Toro, Camilo; Sackett, Jonathan; Karp, Barbara I.; Lungu, Codrin; Alter, Katharine E.; Wu, Tianxia; Ahmad, Omar F.; Villegas, Monica Anne Faye; Auh, Sungyoung; Hallett, Mark

doi:10.1016/j.toxicon.2019.07.010

Cited by 10 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Upper limb dystonia typically presents as dystonic writer’s cramp, task-specific musician’s dystonia, or other occupational or sports dystonia [ 155 , 156 , 157 , 158 ]. Lower limb dystonia can present as foot dystonia (as seen in PD) or performance dystonia (e.g., runner’s dystonia) [ 159 ].…”

Section: Discussion Of Bont Use In Different Indicationsmentioning

confidence: 99%

“…Cole et al [ 168 ] also performed a double-blind RCT of BoNTA in 10 patients with focal hand dystonia and noted subjective improvement in 8 of the 10 patients treated with BoNT. In another study involving 12 patients with writer’s cramp randomized to receive only EMG-guided BoNT therapy or BoNT and occupational therapy, the patient-rated subjective scale scores at 20 weeks were not significantly different between the two groups [ 158 ]. There was a significant decrease (28%) in writer’s cramp impairment scale, but the primary endpoint, patient-rated subjective scale, was not achieved.…”

Section: Discussion Of Bont Use In Different Indicationsmentioning

confidence: 99%

See 1 more Smart Citation

Botulinum Toxin in Movement Disorders: An Update

Anandan

Jankovic

2021

Toxins

View full text Add to dashboard Cite

Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a therapeutic modality for a variety of neurological and non-neurological disorders. With respect to neurologic movement disorders, BoNT has been reported to be effective for the treatment of dystonia, bruxism, tremors, tics, myoclonus, restless legs syndrome, tardive dyskinesia, and a variety of symptoms associated with Parkinson’s disease. More recently, research with BoNT has expanded beyond its use as a powerful muscle relaxant and a peripherally active drug to its potential central nervous system applications in the treatment of neurodegenerative disorders. Although BoNT is the most potent biologic toxin, when it is administered by knowledgeable and experienced clinicians, it is one of the safest therapeutic agents in clinical use. The primary aim of this article is to provide an update on recent advances in BoNT research with a focus on novel applications in the treatment of movement disorders. This comprehensive review of the literature provides a critical review of evidence-based clinical trials and highlights recent innovative pilot studies.

show abstract

Section: Discussion Of Bont Use In Different Indicationsmentioning

confidence: 99%

Section: Discussion Of Bont Use In Different Indicationsmentioning

confidence: 99%

Botulinum Toxin in Movement Disorders: An Update

Anandan

Jankovic

2021

Toxins

View full text Add to dashboard Cite

show abstract

“…Patients in both groups received conventional medical treatments (anti-infection, anticoagulation, rehydration, control of blood pressure and nourishing of the central nervous system), as well as limb rehabilitation training (improving range of motion, transfer exercises, balance exercises, weight loading exercises, stretching exercises, and ability of daily living exercises) [8][9][10].…”

Section: Treatmentsmentioning

confidence: 99%

Effect of combination of botulinum toxin and electromyographic biofeedback therapy on post-stroke patients with lower limb muscle spasticity

Wang¹,

Wang²,

Yu³

2022

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To investigate the clinical effect of combined use of botulinum toxin type A and electromyographic biofeedback therapy (EMGBFT) on post-stroke patients with lower limb muscle spasticity. Methods: The data of 91 post-stroke patients with lower limb muscle spasticity who were admitted to Shanghai Seventh People’s Hospital (January 2020 -January 2021) were retrospectively analyzed, and they were divided into control group (COG, n = 45) and study group (STG, n = 46) based on the treatments given. All patients received conventional rehabilitation and training. Patients in COG were treated with EMGBFT, whereas those in STG received botulinum toxin type A as well as EMGBFT. The parameters determined in the two groups were degree of spasticity, lower limb motor function [3m-Timed Up and Go (3m - TUG) and 10m - Walk Test (10 m - WT)], active range of motion (AROM) of ankle dorsiflexion, ability of daily living (based on Barthel Index, BI), and adverse reactions before and after treatment. Results: The effectiveness of the treatments on spasticity was higher in STG than in COG (p < 0.05). After treatment, the times taken for 3m-TUG and 10m-WT were significantly shorter in STG than in COG (p < 0.05). The AROM of patients in both groups was expanded, but the expansion was significantly greater in STG than in COG (p < 0.05). Conclusion: Combined therapy using botulinum toxin and EMGBFT effectively relieved lower limb muscle spasticity of post-stroke patients, and also improved their lower limb motion function and daily living ability. Thus, the combined therapy provided better management of lower limb spasticity. However, further clinical trials are required prior to its adoption in clinical practice.

show abstract

“…Patientenumfragen haben enttäuschende Ergebnisse gezeigt [18]. Lediglich beim Schreibkrampf wird eine symptomorientierte Ergo therapie empfohlen [26].…”

Section: Orale Medikamente Und Supportive Therapienunclassified

Wissenswertes zu Dystonien

Dresel¹

2020

Nervenheilkunde

View full text Add to dashboard Cite

ZusammenfassungDie Latenz zwischen Manifestation und Diagnose einer primären Dystonie beträgt durchschnittlich mehrere Jahre. Die Diagnose einer primären Dystonie wird durch die Seltenheit der Erkrankung, die Variabilität der klinischen Symptome, die in der Praxis wenig hilfreichen Diagnosekriterien und die Überlappung mit anderen Bewegungsstörungen erschwert. Dieser Artikel gibt einen Überblick über klinische Phänotypen, Pathophysiologie und Therapien primärer Dystonien. Er soll dem Einsteiger und nicht auf Bewegungsstörungen spezialisierten Neurologen Hilfestellungen für den klinischen Alltag geben, um Dystonien frühzeitig zu erkennen und einer Therapie zuzuführen.Der Artikel stellt die 2013 revidierten Diagnosekriterien und die wichtigsten primären Dystonien vor. Pathophysiologisch sind Dystonien durch eine Disinhibition und maladaptive Plastizität in sensomotorischen Hirnnetzwerken charakterisiert. Es ist wichtig, die Dystonie klinisch von anderen Bewegungsstörungen zu differenzieren. Insbesondere eine asymmetrische dystone Haltung der Arme kann ein Frühsymptom einer beginnenden Parkinson-Erkrankung darstellen.Dystonie-Patienten leiden häufig an funktionellen Defiziten, Schmerzen und einer sozialen Stigmatisierung, die zu einer Abnahme der Lebensqualität führen. Therapie der Wahl sind bei fokalen Formen lokale Injektionen von Botulinumtoxin in die dystonen Muskeln und bei multisegmentalen, generalisierten oder therapierefraktären Formen eine Tiefenhirnstimulation des Globus pallidus internus. Beide Therapien führen meist zu einer deutlichen Besserung der dystonen Symptome, einer Linderung der funktionellen Einschränkungen und einer Verbesserung der Lebensqualität. Orale Medikamente haben nur einen geringen Effekt bei ungünstigem Nebenwirkungsprofil und werden nur selten eingesetzt. Begleitend werden Physiotherapie und muskelentspannende Therapien empfohlen, aber der Nachweis für die Wirksamkeit dieser Therapien steht noch aus. Bessere Kenntnisse von Neurologen und Ärzten anderer Fachrichtungen können zu einer früheren Diagnosestellung und effektiveren Therapie von Dystonie-Patienten führen. Ein intensiveres Interesse der Ärzteschaft an diesem Krankheitsbild und eine zunehmende Anzahl an Behandlern und Behandlungszentren können die Versorgung dieser Patienten verbessern.

show abstract

Botulinum toxin and occupational therapy for Writer's cramp

Cited by 10 publications

References 18 publications

Botulinum Toxin in Movement Disorders: An Update

Botulinum Toxin in Movement Disorders: An Update

Effect of combination of botulinum toxin and electromyographic biofeedback therapy on post-stroke patients with lower limb muscle spasticity

Wissenswertes zu Dystonien

Contact Info

Product

Resources

About